myelofibrosis (Cancer)
Information
- Disease name
- myelofibrosis
- Disease ID
- DOID:4971
- Description
- "A myeloid neoplasm that is located in the bone marrow which results in bone marrow being replaced by fibrous (scar) tissue." [url:http\://en.wikipedia.org/wiki/Myelofibrosis]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03069326 | Active, not recruiting | Phase 2 | A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis | February 27, 2017 | February 2025 |
| NCT04603495 | Active, not recruiting | Phase 3 | Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) | April 9, 2021 | December 2027 |
| NCT04551066 | Active, not recruiting | Phase 3 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | May 27, 2021 | July 31, 2024 |
| NCT03912064 | Active, not recruiting | Phase 1 | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | July 10, 2019 | July 1, 2024 |
| NCT04640025 | Active, not recruiting | Phase 2 | A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib | March 10, 2021 | June 22, 2026 |
| NCT04562870 | Active, not recruiting | Phase 2 | A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated Myelofibrosis | March 17, 2021 | January 6, 2025 |
| NCT04679870 | Active, not recruiting | Phase 2 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis | June 9, 2021 | June 30, 2026 |
| NCT02158858 | Active, not recruiting | Phase 1/Phase 2 | A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis | July 16, 2014 | October 31, 2024 |
| NCT06388759 | Active, not recruiting | Phase 1 | TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients | August 1, 2022 | December 2024 |
| NCT00719888 | Active, not recruiting | Phase 2 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | November 18, 2005 | December 22, 2024 |
| NCT05972577 | Active, not recruiting | N/A | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | June 2, 2021 | December 31, 2024 |
| NCT04551053 | Active, not recruiting | Phase 3 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | May 26, 2021 | July 31, 2024 |
| NCT02396134 | Active, not recruiting | Phase 2 | Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | May 21, 2015 | December 31, 2024 |
| NCT04328844 | Active, not recruiting | Phase 1 | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | February 25, 2020 | April 2024 |
| NCT03645824 | Active, not recruiting | Phase 2 | Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) | June 4, 2018 | February 2027 |
| NCT03560752 | Active, not recruiting | Phase 1 | CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant | August 20, 2018 | June 18, 2024 |
| NCT03480360 | Active, not recruiting | Phase 3 | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | March 28, 2018 | September 13, 2025 |
| NCT03427866 | Active, not recruiting | Phase 2 | Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. | August 28, 2018 | May 2025 |
| NCT02493530 | Active, not recruiting | Phase 1 | TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea | July 2015 | December 2024 |
| NCT02506933 | Active, not recruiting | Phase 2 | Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant | November 5, 2015 | December 30, 2024 |
| NCT02530034 | Active, not recruiting | Phase 1 | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | January 31, 2019 | January 31, 2026 |
| NCT03333486 | Active, not recruiting | Phase 2 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | December 7, 2017 | August 28, 2024 |
| NCT04097821 | Active, not recruiting | Phase 1/Phase 2 | Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients | September 26, 2019 | July 31, 2024 |
| NCT03289910 | Active, not recruiting | Phase 2 | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | September 24, 2018 | December 21, 2024 |
| NCT04060277 | Active, not recruiting | Phase 2 | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation | November 27, 2019 | April 7, 2030 |
| NCT03952039 | Active, not recruiting | Phase 3 | An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | September 16, 2019 | June 23, 2025 |
| NCT04817007 | Active, not recruiting | Phase 1/Phase 2 | A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) | March 22, 2021 | May 31, 2026 |
| NCT03723148 | Available | Individual Patient Compassionate Use of Fedratinib | |||
| NCT00807677 | Completed | Phase 1 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies | March 2009 | March 2013 |
| NCT00934544 | Completed | Phase 3 | Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial | July 1, 2009 | March 4, 2015 |
| NCT00975975 | Completed | Phase 2 | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | September 2009 | November 2013 |
| NCT00997386 | Completed | Phase 2 | Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States | September 2009 | January 2016 |
| NCT01149681 | Completed | Phase 2 | Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis | July 2010 | February 2011 |
| NCT01290302 | Completed | Phase 1 | Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia | October 2010 | |
| NCT01317875 | Completed | Phase 1 | Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) | March 31, 2011 | December 31, 2019 |
| NCT01340651 | Completed | Phase 2 | Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients | March 2011 | July 2012 |
| NCT01369498 | Completed | Phase 2 | Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis | June 30, 2011 | September 24, 2014 |
| NCT01398462 | Completed | Phase 1 | Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | July 2011 | December 2015 |
| NCT01417520 | Completed | Clinical and Pathophysiological Investigations Into Erdheim Chester Disease | August 1, 2011 | July 24, 2019 | |
| NCT00069680 | Completed | Genetic Analysis of Gray Platelet Syndrome | September 29, 2003 | May 17, 2018 | |
| NCT01499147 | Completed | N/A | Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies | February 2000 | May 2013 |
| NCT01520220 | Completed | Phase 1 | Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms | June 11, 2012 | February 24, 2017 |
| NCT01692366 | Completed | Phase 2 | Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly | November 2012 | March 2014 |
| NCT01693601 | Completed | Phase 1/Phase 2 | Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) | January 2013 | May 18, 2018 |
| NCT01712308 | Completed | Phase 2 | Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia | February 21, 2013 | May 24, 2022 |
| NCT01760655 | Completed | Phase 2 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | December 24, 2012 | December 5, 2022 |
| NCT01795677 | Completed | Phase 2 | JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis | December 2012 | March 2019 |
| NCT01814475 | Completed | Phase 2 | Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis | July 2011 | December 31, 2016 |
| NCT01956799 | Completed | Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy | May 2013 | December 2019 | |
| NCT02065154 | Completed | Phase 2 | Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis | August 27, 2013 | April 2022 |
| NCT02129582 | Completed | Phase 1 | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies | November 5, 2014 | March 5, 2020 |
| NCT02167958 | Completed | Phase 1 | Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source | February 11, 2015 | September 21, 2019 |
| NCT02181478 | Completed | Early Phase 1 | Intra-Osseous Co-Transplant of UCB and hMSC | July 22, 2015 | February 7, 2020 |
| NCT02268253 | Completed | Phase 2 | Tagraxofusp (SL-401) in Patients With CMML or MF | December 2014 | March 7, 2023 |
| NCT02370706 | Completed | Phase 1 | Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis | May 21, 2015 | November 9, 2020 |
| NCT02426086 | Completed | Phase 2 | Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor | August 28, 2015 | February 7, 2020 |
| NCT02556931 | Completed | Phase 2 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | December 2015 | April 2021 |
| NCT02581007 | Completed | Phase 2 | Reduced Intensity Conditioning Transplant Using Haploidentical Donors | October 26, 2015 | December 28, 2020 |
| NCT02593760 | Completed | Phase 1 | A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF) | January 25, 2016 | July 12, 2017 |
| NCT02660281 | Completed | Phase 1 | URMC Related Haplo-identical Donor BMT | October 2015 | January 7, 2021 |
| NCT01493414 | Completed | Phase 3 | INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. | August 16, 2011 | January 26, 2017 |
| NCT00081874 | Completed | Phase 1/Phase 2 | RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma | April 2004 | September 2006 |
| NCT00087672 | Completed | Phase 2 | A Phase II Study of CC-5013 in Myelofibrosis | July 2004 | February 2009 |
| NCT00136409 | Completed | Phase 2 | A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) | May 2002 | December 2008 |
| NCT00235391 | Completed | Phase 3 | Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload | October 2005 | October 2008 |
| NCT00255346 | Completed | Phase 2 | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | November 15, 2005 | March 3, 2017 |
| NCT00287261 | Completed | Phase 2 | A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM) | February 2006 | March 2008 |
| NCT00309842 | Completed | Phase 2 | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases | July 28, 2005 | November 22, 2019 |
| NCT00352794 | Completed | Phase 2 | Lenalidomide for Patients With Myelofibrosis (MF) | July 7, 2006 | March 8, 2018 |
| NCT00354120 | Completed | Phase 2/Phase 3 | Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant | March 2005 | August 2011 |
| NCT00360035 | Completed | Phase 2 | Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia | July 2006 | February 2009 |
| NCT00463385 | Completed | Phase 2 | A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia | April 1, 2007 | December 31, 2013 |
| NCT00475020 | Completed | Phase 2 | Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome | January 4, 2006 | October 4, 2017 |
| NCT00494585 | Completed | Phase 2 | CEP-701 for PH-negative Myelofibrosis | June 2007 | May 2010 |
| NCT00509899 | Completed | Phase 1/Phase 2 | Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis | June 2007 | February 2017 |
| NCT00569660 | Completed | Phase 2 | Ph II Study of Azacitidine in Myelofibrosis | June 2005 | April 2008 |
| NCT00572065 | Completed | Early Phase 1 | Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis | February 29, 2008 | February 8, 2010 |
| NCT00572897 | Completed | Phase 2 | Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis | August 2007 | June 15, 2015 |
| NCT00599547 | Completed | Phase 2 | Allogeneic Stem Cell Transplantation (SCT) After Dose-reduced Conditioning for Myelofibrosis Patients | November 2002 | December 2009 |
| NCT00606437 | Completed | Phase 1 | Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants | September 2005 | February 2014 |
| NCT00631462 | Completed | Phase 1 | A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis | January 2008 | October 2009 |
| NCT00665067 | Completed | Correlative Biomarker Study in Patients With Myeloproliferative Disorders | April 2007 | July 20, 2018 | |
| NCT00666549 | Completed | Research Tissue Bank | September 2007 | March 27, 2017 | |
| NCT00715247 | Completed | Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes | July 2006 | December 2018 | |
| NCT00719836 | Completed | Phase 1/Phase 2 | A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies | August 2008 | January 2012 |
| NCT00723333 | Completed | Bone Marrow Transplant Chart Review for RIC | May 2008 | July 2009 | |
| NCT00724334 | Completed | Phase 1/Phase 2 | A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis | July 2008 | May 2014 |
| NCT00745550 | Completed | Phase 1/Phase 2 | A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis | August 2008 | January 2012 |
| NCT02742324 | Completed | Phase 1/Phase 2 | Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg | March 2016 | December 31, 2021 |
| NCT02765724 | Completed | Phase 1 | Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects | January 2015 | June 2015 |
| NCT02784496 | Completed | Phase 2 | Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis | September 29, 2016 | January 23, 2024 |
| NCT02807077 | Completed | Phase 1 | PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects | November 2014 | July 2015 |
| NCT02910258 | Completed | Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis | September 2012 | March 2017 | |
| NCT02916979 | Completed | Phase 1 | Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG | September 6, 2016 | February 11, 2022 |
| NCT03136185 | Completed | Phase 1/Phase 2 | Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) | July 18, 2017 | March 8, 2022 |
| NCT03566446 | Completed | Phase 1 | CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms | June 20, 2018 | April 30, 2021 |
| NCT03745378 | Completed | Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) | May 15, 2018 | September 30, 2018 | |
| NCT03755518 | Completed | Phase 3 | A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | March 27, 2019 | November 8, 2023 |
| NCT03886415 | Completed | Phase 2 | Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis. | January 8, 2019 | February 2, 2021 |
| NCT03907436 | Completed | N/A | The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase | October 1, 2018 | October 1, 2019 |
| NCT04153305 | Completed | European Registry for Myeloproliferative Neoplasms (MPNs) - Update of ERNEST Study | October 8, 2019 | December 31, 2020 | |
| NCT04218071 | Completed | Phase 2 | Actuate 1901: 9-ING-41 in Myelofibrosis | August 20, 2020 | January 18, 2024 |
| NCT04282421 | Completed | Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in France | January 1, 2007 | February 1, 2020 | |
| NCT04617028 | Completed | Phase 3 | Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis | February 5, 2021 | October 18, 2023 |
| NCT04629430 | Completed | N/A | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT | February 19, 2021 | October 28, 2022 |
| NCT04629508 | Completed | Phase 2 | To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) | July 12, 2021 | August 24, 2023 |
| NCT04666025 | Completed | SARS-CoV-2 Donor-Recipient Immunity Transfer | September 23, 2020 | May 5, 2023 | |
| NCT04851535 | Completed | Phase 2 | Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment. | July 28, 2021 | November 1, 2022 |
| NCT05410470 | Completed | Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis | August 2012 | December 2021 | |
| NCT05444972 | Completed | A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review | August 23, 2022 | November 14, 2023 | |
| NCT05982106 | Completed | Phase 1 | To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects | July 19, 2021 | July 28, 2021 |
| NCT06132243 | Completed | Phase 1 | Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions | November 29, 2023 | December 20, 2023 |
| NCT03592576 | No longer available | Expanded Access to Navitoclax | |||
| NCT05582083 | No longer available | Managed Access Program for Momelotinib in Myelofibrosis | |||
| NCT05710211 | Not yet recruiting | N/A | Clonal Architecture of ASXL1-mutated Myelofibrosis | March 2023 | March 2029 |
| NCT06024915 | Not yet recruiting | Phase 1 | A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets | September 2023 | December 2023 |
| NCT04709458 | Not yet recruiting | Phase 1 | Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis | September 1, 2022 | October 28, 2024 |
| NCT05762874 | Not yet recruiting | Ruxolitinib in Patients With Myelofibrosis | March 2023 | June 2025 | |
| NCT05875805 | Not yet recruiting | N/A | A Telehealth Advance Care Planning Intervention | April 1, 2024 | December 31, 2025 |
| NCT06397313 | Not yet recruiting | Phase 2 | RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis | September 2024 | October 2027 |
| NCT06398457 | Not yet recruiting | Early Phase 1 | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies | June 2024 | December 2026 |
| NCT06345495 | Not yet recruiting | Phase 2 | High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly | September 30, 2024 | January 1, 2029 |
| NCT05665192 | Recruiting | A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib | August 2, 2021 | December 31, 2025 | |
| NCT06063486 | Recruiting | Phase 2 | Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms | March 1, 2024 | March 1, 2027 |
| NCT04176198 | Recruiting | Phase 1/Phase 2 | A Study of Oral TP-3654 in Patients With Myelofibrosis | December 16, 2019 | April 30, 2030 |
| NCT04217356 | Recruiting | Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis | August 5, 2020 | February 5, 2026 | |
| NCT06122831 | Recruiting | Phase 1/Phase 2 | A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) | December 12, 2023 | April 2027 |
| NCT04279847 | Recruiting | Phase 1 | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms | February 23, 2021 | December 31, 2024 |
| NCT05980806 | Recruiting | Phase 2 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | April 22, 2024 | October 2028 |
| NCT06001385 | Recruiting | Phase 2 | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | December 8, 2023 | June 30, 2026 |
| NCT03452774 | Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | January 1, 2018 | June 2027 | |
| NCT03314974 | Recruiting | Phase 2 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | March 30, 2018 | November 10, 2025 |
| NCT04485260 | Recruiting | Phase 1/Phase 2 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib | January 28, 2021 | October 2024 |
| NCT03802695 | Recruiting | Phase 1 | A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | April 8, 2019 | April 2028 |
| NCT03878199 | Recruiting | Phase 1/Phase 2 | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | February 20, 2019 | December 31, 2024 |
| NCT04562389 | Recruiting | Phase 3 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | March 11, 2021 | March 2028 |
| NCT02934477 | Recruiting | Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis | November 2016 | October 2027 | |
| NCT04576156 | Recruiting | Phase 3 | A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment | April 12, 2021 | April 27, 2027 |
| NCT06059391 | Recruiting | Phase 2 | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | August 30, 2024 | January 1, 2028 |
| NCT06150157 | Recruiting | Phase 1 | A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms | December 20, 2023 | November 19, 2026 |
| NCT06164561 | Recruiting | 18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study. | November 21, 2023 | December 2025 | |
| NCT06245941 | Recruiting | Phase 1/Phase 2 | A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) | May 13, 2024 | May 2027 |
| NCT01962636 | Recruiting | N/A | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | December 2016 | October 2025 |
| NCT04640532 | Recruiting | Phase 1/Phase 2 | KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF | November 17, 2020 | July 24, 2025 |
| NCT04655118 | Recruiting | Phase 2 | Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis | October 22, 2020 | December 31, 2025 |
| NCT04676529 | Recruiting | Phase 1/Phase 2 | Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis | February 18, 2021 | August 2025 |
| NCT01973881 | Recruiting | Quantitative MRI for Myelofibrosis | December 22, 2014 | December 2026 | |
| NCT04717414 | Recruiting | Phase 3 | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions | February 25, 2021 | August 23, 2025 |
| NCT04771572 | Recruiting | Phase 1 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | August 23, 2021 | October 1, 2025 |
| NCT06351631 | Recruiting | Phase 3 | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) | May 23, 2024 | December 4, 2034 |
| NCT03964506 | Recruiting | Early Phase 1 | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant | July 1, 2020 | March 1, 2025 |
| NCT04888741 | Recruiting | Phase 2 | Methods of T Cell Depletion Trial (MoTD) | February 22, 2021 | January 2026 |
| NCT04988815 | Recruiting | Phase 2 | Ropeginterferon Alfa 2b for Early Myelofibrosis | September 1, 2021 | December 31, 2025 |
| NCT05025488 | Recruiting | Phase 1 | Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm | April 4, 2023 | March 2026 |
| NCT05031897 | Recruiting | Phase 2 | Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | October 25, 2021 | October 1, 2024 |
| NCT05037760 | Recruiting | Phase 2 | Study to Evaluate KER-050 as a Monotherapy or in Combination With Ruxolitinib in Myelofibrosis | December 16, 2021 | June 2025 |
| NCT05123365 | Recruiting | Phase 1/Phase 2 | An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms | January 3, 2022 | November 15, 2026 |
| NCT05233618 | Recruiting | Phase 1 | Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002) | July 13, 2022 | October 1, 2026 |
| NCT05279001 | Recruiting | Phase 1 | A Safety and Tolerability Study of Jaktinib | July 1, 2024 | November 30, 2025 |
| NCT05320198 | Recruiting | Phase 1/Phase 2 | Study of DISC-0974 in Participants With Myelofibrosis and Anemia | June 6, 2022 | October 2024 |
| NCT05280509 | Recruiting | Phase 1/Phase 2 | Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib | June 9, 2022 | April 2027 |
| NCT05371964 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | May 4, 2022 | August 2027 |
| NCT06378437 | Recruiting | Phase 1 | A Study of GLB-001 in Patients With Myeloid Malignancies | May 24, 2024 | December 31, 2027 |
| NCT05423691 | Recruiting | Phase 1 | Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs | December 27, 2022 | April 30, 2024 |
| NCT05805605 | Recruiting | Phase 2 | Allo HSCT Using RIC and PTCy for Hematological Diseases | May 1, 2023 | October 22, 2028 |
| NCT05447260 | Recruiting | Phase 4 | A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis | June 10, 2022 | December 10, 2023 |
| NCT05455294 | Recruiting | Phase 1 | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | July 18, 2022 | December 31, 2026 |
| NCT05535764 | Recruiting | Phase 1 | Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis | March 23, 2023 | October 30, 2027 |
| NCT05569538 | Recruiting | Phase 2 | Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis | December 1, 2022 | December 31, 2025 |
| NCT01758042 | Recruiting | N/A | Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders | November 2012 | July 2027 |
| NCT00393380 | Terminated | Phase 2 | Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor | September 2006 | March 2012 |
| NCT02435550 | Terminated | N/A | iCare for Cancer Patients | June 26, 2015 | October 1, 2019 |
| NCT01758588 | Terminated | Phase 2 | Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis | January 2013 | June 2017 |
| NCT01730248 | Terminated | Phase 1 | A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis | December 18, 2012 | September 28, 2017 |
| NCT01300611 | Terminated | Phase 1 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation | January 2011 | December 2020 |
| NCT04543279 | Terminated | Phase 2 | Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia | May 3, 2021 | July 30, 2022 |
| NCT01291784 | Terminated | Phase 1 | Anti-TGF-beta Therapy in Patients With Myelofibrosis | February 2011 | January 2013 |
| NCT00852709 | Terminated | Phase 1 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias | September 1, 2007 | November 20, 2009 |
| NCT00667277 | Terminated | Phase 2 | Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis | March 2008 | March 2010 |
| NCT00594308 | Terminated | N/A | In-Vivo Activated T-Cell Depletion to Prevent GVHD | October 2007 | |
| NCT00522990 | Terminated | Phase 1/Phase 2 | Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias | September 2006 | April 2009 |
| NCT00522574 | Terminated | Phase 1 | A Safety Study of XL019 in Adults With Myelofibrosis | August 2007 | |
| NCT04866056 | Terminated | Phase 1/Phase 2 | Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. | September 30, 2021 | June 10, 2022 |
| NCT02728700 | Terminated | Phase 1 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT | February 2016 | July 2018 |
| NCT02730884 | Terminated | Phase 2 | Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia | August 16, 2017 | August 22, 2019 |
| NCT02877082 | Terminated | Phase 2 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | September 2016 | July 2017 |
| NCT03373877 | Terminated | Phase 1 | Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis | May 24, 2018 | March 10, 2020 |
| NCT02440685 | Terminated | Phase 1/Phase 2 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | May 2015 | July 2018 |
| NCT02436135 | Terminated | Phase 1 | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease | June 5, 2015 | November 20, 2017 |
| NCT00668421 | Unknown status | Phase 1/Phase 2 | CEP-701 (Lestaurtinib) in Myelofibrosis | April 2008 | January 2015 |
| NCT02530619 | Unknown status | N/A | Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia | October 9, 2015 | May 2022 |
| NCT03959371 | Unknown status | Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy | April 11, 2017 | December 31, 2021 | |
| NCT04728490 | Unknown status | Phase 2 | Haplo-identical Transplantation in Patients With Myelofibrosis - A Phase 2 Prospective Multicentric Prospective Study | January 30, 2021 | January 30, 2024 |
| NCT04464889 | Withdrawn | Phase 1 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | July 2, 2020 | July 2025 |
| NCT04283526 | Withdrawn | Phase 1 | Study of Select Combinations in Adults With Myelofibrosis | November 30, 2020 | April 11, 2024 |
| NCT00148980 | Withdrawn | Phase 2 | Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation | April 2003 | |
| NCT02469974 | Withdrawn | N/A | Ruxolitinib in Combination With Autotransplant | May 2015 | August 2016 |
| NCT03438344 | Withdrawn | Phase 2 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | December 2018 | December 2021 |
| NCT04354727 | Withdrawn | Phase 1/Phase 2 | A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy | December 15, 2020 | June 15, 2023 |
| NCT02805868 | Withdrawn | Early Phase 1 | Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | June 2016 | |
| NCT02663648 | Withdrawn | Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders | June 2016 | June 2020 | |
| NCT03602898 | Withdrawn | Phase 2 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | June 1, 2021 | September 17, 2023 |
| NCT02564536 | Withdrawn | Phase 1 | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | June 2017 | June 30, 2020 |
- Disase is a (Disease Ontology)
- DOID:0070004
- Cross Reference ID (Disease Ontology)
- GARD:8618
- Cross Reference ID (Disease Ontology)
- ICD10CM:D47.4
- Cross Reference ID (Disease Ontology)
- ICD10CM:D75.81
- Cross Reference ID (Disease Ontology)
- ICD9CM:238.76
- Cross Reference ID (Disease Ontology)
- ICD9CM:289.83
- Cross Reference ID (Disease Ontology)
- MESH:D055728
- Cross Reference ID (Disease Ontology)
- MIM:254450
- Cross Reference ID (Disease Ontology)
- NCI:C2862
- Cross Reference ID (Disease Ontology)
- NCI:C3248
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:128843003
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:267572005
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0001815
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0026987
- Exact Synonym (Disease Ontology)
- Agnogenic myeloid metaplasia
- Exact Synonym (Disease Ontology)
- Aleukemic myelosis
- Exact Synonym (Disease Ontology)
- bone Marrow Fibrosis
- Exact Synonym (Disease Ontology)
- Megakaryocytic myelosclerosis
- Exact Synonym (Disease Ontology)
- myelosclerosis
- Exact Synonym (Disease Ontology)
- primary myelofibrosis
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0011974